CJC 1295 is one of the most popular peptides besides the known GHRP 2 and GHRP 6. It is mostly used in the stack because of its potency and reinforcing properties of other peptides. You can find out more about CJC 1295 here:
CJC-1295 is an injectable peptide used to increase growth hormone production. This peptide is a growth hormone releasing hormone, also called GHRH. This means that it acts in the same way as GHRH and can be called a GHRH.
It is important not to confuse CJC 1295 with CJC 1295 w / o DAC. The latter is not the same as CJC 1295. If a peptide does not have a DAC, then it is not CJC 1295. CJC 1295 is sometimes offered as a CJC 1295 with DAC. This is nothing more than CJC 1295.
These two products, CJC 1295 and CJC 1295 w / o DAC, differ mainly in their duration of action. CJC 1295 w / o DAC has a short duration of action, which requires a lower dosage at small injection intervals, whereas CJC 1295 has a longer duration of action, which makes a high dose possible with less frequent injections. Thus, quasi short and long esters are bound to these CJC types, comparatively like testosterone enanthate and propionate.
CJC 1295 belongs, as I said, to the class of Growth Hormone Releasing Hormones, GHRH. GHRH is also the name of the naturally occurring hormone in the body, but the natural compound is not used in the field of bodybuilding or as a high-performance active substance due to the high production costs and the extremely short duration of action. CJC 1295 is a modified version of the first 29 amino acids of GHRH in combination with the addition of a Drug Affinity Complex or DAC. The combination of the modifications provides a half-life of about one week and stable blood levels after injection.
The primary use of CJC 1295 is to provide increased growth hormone levels, which also results in elevated IGF-1 levels. An increase in these levels can have a very positive effect on fat reduction and muscle building. In general, a product from the GHRH category including CJC 1295 is used as an alternative to injectable growth hormones and rarely combined with injectable growth hormones.
This product is best suited for cases where you need support for your growth hormone production or a maximum or nearly maximum increase in growth hormone production, which depends entirely on the CJC 1295 variant and the way of injection. This is because the blood level provides both CJC 1295 and CJC 1295 w / o DAC. However, the uniform levels can also provide very good support for natural pulsating growth hormone thrusts.
CJC 1295 increases the body's growth hormone production in the same way as GHRH. However, administration does not initiate a pulsatile growth hormone release. Since CJC 1295 provides stable blood levels, it increases the amplitude of the natural pulsatile growth hormone thrusts on a continuous basis. CJC 1295 can be combined particularly efficiently with a GHRP, since the mode of action of both peptides not only adds, but also increases their effect, since the combination ensures an even more radical release of growth hormones.
The injection can be made subcutaneously, intramuscularly or intravenously, depending on the personal choice. If desired, peptide solutions can be applied from other ampoules such as, for example, a GHRP with the same syringe. This can reduce the number of injections.
Regarding the dosage, a dose of 100-200 mcg of CJC 1295 w / o DAC per injection, which should be injected 3 times daily, as well as GHRP 2 or 6, should be injected into the HGH peak times for the best possible effect:
CJC 1295 w / o DAC can be perfectly combined with a GHRP. If you want to combine CJC 1295 with a GHRP, the recommended dosage of CJC 1295 is the above recommended amount, while the GHRP dosage is about 125mcg-250mcg. The peptides can be directly drawn together.
As for the dosage, a dose of 1000 mcg of CJC 1295 per injection is recommended twice a week, which is made possible by the attached Drug Affinity Complex, which makes the CJC 1295 a long-lasting peptide as mentioned above.
The known effects and advantages of these CJC 1295 variants include all GHRH or GHRP typical factors:
Relative rarely, in the use of CJC 1295 peptides, unwanted side effects that are associated with excessive use of growth hormones, such as pain caused by compression of nerves, headaches, excessive water retention or reduced insulin sensitivity can occur, which often results in fatigue. The reason for this is the stimulation of a higher growth hormone production than would be adequate for the individual case. The solution to this problem is to end the use of CJC 1295 until the problem has disappeared and to use a lower dosage when the use continues.